JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.02475-07v1
82/12/6061    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Keck, Z.-Y.
Right arrow Articles by Foung, S. K. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keck, Z.-Y.
Right arrow Articles by Foung, S. K. H.

 Previous Article  |  Next Article 

Journal of Virology, June 2008, p. 6061-6066, Vol. 82, No. 12
0022-538X/08/$08.00+0     doi:10.1128/JVI.02475-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies{triangledown}

Zhen-Yong Keck,1 Ta-Kai Li,1 Jinming Xia,1 Meital Gal-Tanamy,2 Oakley Olson,1 Sophia H. Li,1 Arvind H. Patel,3 Jonathan K. Ball,4 Stanley M. Lemon,2 and Steven K. H. Foung1*

Department of Pathology, Stanford University School of Medicine, Stanford, California 94305,1 Center for Hepatitis Research, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas 77555-1073,2 MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, United Kingdom,3 Institute of Infection, Immunity and Inflammation, School of Molecular Medical Sciences, the University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom4

Received 16 November 2007/ Accepted 2 April 2008

Development of a successful hepatitis C virus (HCV) vaccine requires the definition of neutralization epitopes that are conserved among different HCV genotypes. Five human monoclonal antibodies (HMAbs) are described that cross-compete with other antibodies to a cluster of overlapping epitopes, previously designated domain B. Each HMAb broadly neutralizes retroviral pseudotype particles expressing HCV E1 and E2 glycoproteins, as well as the infectious chimeric genotype 1a and genotype 2a viruses. Alanine substitutions of residues within a region of E2 involved in binding to CD81 showed that critical E2 contact residues involved in the binding of representative antibodies are identical to those involved in the binding of E2 to CD81.

* Corresponding author. Mailing address: Stanford Medical School Blood Center, 3373 Hillview Avenue, Palo Alto, CA 94304. Phone: (650) 723-6481. Fax: (650) 725-6610. E-mail: sfoung{at}stanford.edu

{triangledown} Published ahead of print on 9 April 2008.

Journal of Virology, June 2008, p. 6061-6066, Vol. 82, No. 12
0022-538X/08/$08.00+0     doi:10.1128/JVI.02475-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.